.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CC01_Demecolcine.Demecolcine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CC01_Demecolcine.Demecolcine| name: | Demecolcine | |
| ATC code: | L01CC01 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 2 | mg |
| volume of distribution: | 3 | L |
| clearance: | 5 | L/h |
| other parameters in model implementation | ||
Demecolcine (colcemid) is an antimitotic agent, a colchicine analog that binds to tubulin and inhibits microtubule polymerization, preventing cell division. Historically, it was used in cytogenetics for inducing metaphase arrest in chromosomes, and as an anti-cancer agent. Demecolcine is no longer widely approved or used clinically due to toxicity concerns.
No published clinical pharmacokinetic studies reporting detailed parameters for demecolcine in humans have been found. Parameters below are rough estimates extrapolated from limited preclinical/animal literature or based on colchicine-related analogs.